1. Rituximab was associated with lower discontinuation rates as compared to other disease-modifying treatments in newly diagnosed patients with relapsing-remitting ...
1. Patients with mantle cell lymphoma treated with autologous stem cell transplantation experienced greater overall, event-free, and progression-free survival when ...
1. Compared to standard chemotherapy alone, the addition of the rituximab significantly improves event-free survival among adults with CD20-positive, Philadelphia ...
Rituximab maintenance for a maximum of 5 years after single-agent Rituximab induction in follicular lymphoma: Results of the randomized ...
1. Induction therapy and maintenance therapy for mantle-cell lymphoma with lenalidomide plus rituximab was found to be effective and safe. 2. ...
1. This retrospective analysis examined 24 children with steroid-resistant nephrotic syndrome, all initially treated with rituximab after failing traditional therapies ...
1. The addition of lenalidomide to standard R-CHOP chemotherapy reduced the negative prognostic impact of non-GCB phenotype in diffuse large ...
![Improved hematologic cancer survival in Europe over a 15 year period [EUROCARE-5 study]](https://www.2minutemedicine.com/wp-content/uploads/2014/07/700px-Europe_polar_stereographic_Caucasus_Urals_boundary.svg_-350x250.png)
1. Survival improved for most types of hematologic malignancies in Europe between 1992 and 2007. 2. The improvements in survival ...
Image: PD 1. Most treatment-naïve patients with chronic lymphocytic leukemia (CLL) safely tolerated escalating doses of combined lenalidomide and rituximab. 2. ...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the ...
